SCHEMBL3018604

SCHEMBL3018604

Cc1ccc(C(=O)Nc2ccnc(C(C)(C)C)c2)cc1Nc1ncnn1-c1cc(NCCCN2CCOCC2)ncn1

nearest known ligand 0.58

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 7/20 0.58
LCK P06239 8/20 0.52
INSR P06213 7/20 0.52
LYN P07948 7/20 0.52
SRC P12931 7/20 0.52
KDR P35968 7/20 0.52
HCK P08631 6/20 0.52
BRAF P15056 5/20 0.51
RAF1 P04049 2/20 0.43
ARAF P10398 2/20 0.43
ALDH1A1 P00352 1/20 0.43
LMNA P02545 1/20 0.43
GAA P10253 1/20 0.43
MAPT P10636 1/20 0.43
HTT P42858 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3020918 0.96 MAPK14 (0.52) MAPK14LCKINSRLYNSRC
SCHEMBL3015581 0.93 INSR (0.59) MAPK14LCKINSRLYNSRC
SCHEMBL3014310 0.91 MAPK14 (0.57) MAPK14LCKINSRLYNSRC
SCHEMBL3017502 0.90 INSR (0.52) MAPK14LCKINSRLYNSRC
SCHEMBL3004654 0.86 LCK (0.67) MAPK14LCKINSRLYNSRC
SCHEMBL3009092 0.86 MAPK14 (0.56) MAPK14LCKINSRLYNSRC
SCHEMBL3021117 0.86 LCK (0.53) LCKINSRLYNSRCKDR
SCHEMBL3020814 0.85 LCK (0.51) MAPK14LCKINSRLYNSRC
SCHEMBL3017957 0.83 BRAF (0.47) MAPK14LCKINSRLYNSRC
SCHEMBL3021329 0.82 LCK (0.67) MAPK14LCKINSRLYNSRC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100184765-A1 Protein Kinase Inhibitors and Methods for Using Thereof IRM LLC 2010-07-22 US claimed
EP-2170867-A1 PROTEIN KINASE INHIBITORS AND METHODS FOR USING THEREOF IRM LLC (BM) 2010-04-07 EP claimed
WO-2008157131-A1 PROTEIN KINASE INHIBITORS AND METHODS FOR USING THEREOF IRM LLC (BM) 2008-12-24 WO claimed
US-20100184765-A1 Protein Kinase Inhibitors and Methods for Using Thereof IRM LLC 2010-07-22 US disclosed
US-20100184765-A1 Protein Kinase Inhibitors and Methods for Using Thereof IRM LLC 2010-07-22 US disclosed
US-20100184765-A1 Protein Kinase Inhibitors and Methods for Using Thereof IRM LLC 2010-07-22 US disclosed
EP-2170867-A1 PROTEIN KINASE INHIBITORS AND METHODS FOR USING THEREOF IRM LLC (BM) 2010-04-07 EP disclosed
WO-2008157131-A1 PROTEIN KINASE INHIBITORS AND METHODS FOR USING THEREOF IRM LLC (BM) 2008-12-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100184765-A1 Protein Kinase Inhibitors and Methods for Using Thereof BMX, FRK, FYN MAPK14 603/4885LCK 8/4885INSR 1712/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.